Dr Keith Chappell discusses the bivalent recombinant vaccine for COVID-19 following the study by Dayan and colleagues, with focus on vaccine access, variants and boosters, tolerability and side effects, as well as hopes for future trials.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv